Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients
Downloads
Introduction: The regimen of drug-resistant tuberculosis (DR-TB) is Bedaquiline. One of the adverse events is QT interval prolongation, which can increase the risk of Torsade de Pointes (TdP) and lead to death. DR-TB patient screening before starting the treatment and monitoring QT interval during the treatment should be performed. This study aimed to determine Bedaquiline correlation to QT interval prolongation in DR-TB patients.
Methods: This was a retrospective study using an observational design by viewing medical records of DR-TB patients who underwent treatment from January 2019 to March 2022.
Results: This study involved 46 DR-TB patients with an average age of 41.4 years old, and 58.7% were males with a regimen of Bedaquiline. The comparison of Baseline QT intervals before and after one month of therapy showed QT interval prolongation (457.1 ± 18.2 ms and 443.8 ± 10.2 ms; p < 0.001). The comparison of QT intervals before the therapy and six months after the therapy showed prolongation QT intervals (443.8 ± 10.2 ms and 458.4 ± 23.7 ms; p < 0.001). QT intervals after one month of therapy compared to six months after the therapy showed insignificant slight prolongation (457.1 ± 18.2 ms and 458.4 ± 23.7 ms; p = 0.587).
Conclusion: QT interval prolongation occurred in DR-TB patients who received treatment using Bedaquiline regimen. It was seen significantly between baseline QT interval and after receiving the therapy for one month and six months.
Gotham D, McKenna L, Frick M, et al. Public Investments in the Clinical Development of Bedaquiline. PLoS One 2020; 15: e0239118-. [PubMed]
Mase S, Chorba T, Lobue P, et al. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis. MMWR Recommendations and Reports; 62. [PubMed]
Bélard S, Heuvelings CC, Janssen S, et al. Bedaquiline for the Treatment of Drug-Resistant Tuberculosis. Expert Rev Anti Infect Ther 2015; 13: 535–553. [PubMed]
Kwon Y. Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis. Chonnam Med J 2017; 53: 103. [PubMed]
Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the Treatment of Multidrug- and Extensively Drug-Resistant Tuberculosis. Eur Respir J 2016; 47: 564. [PubMed]
Diacon A, Pym A, Grobusch M, et al. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. N Engl J Med 2014; 371: 723–732. [PubMed]
Wang MG, Wu SQ, He JQ. Efficacy of Bedaquiline in the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. BMC Infect Dis 2021; 21: 970. [PubMed]
Field SK. Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis: Great Promise or Disappointment? Ther Adv Chronic Dis 2015; 6: 170–184. [PubMed]
Pontali E, Sotgiu G, Tiberi S, et al. Cardiac Safety of Bedaquiline: A Systematic and Critical Analysis of the Evidence. Eur Respir J 2017; 50: 1701462. [PubMed]
Postema P, Wilde A. The Measurement of the QT Interval. Curr Cardiol Rev; 10. Epub ahead of print 13 May 2014. [PubMed]
Guo H, Courbon GM, Bueler SA, et al. Structure of Mycobacterial ATP Synthase Bound to the Tuberculosis Drug Bedaquiline. Nature 2021; 589: 143–147. [PubMed]
Lakshmanan M, Xavier A. Bedaquiline - The First ATP Synthase Inhibitor against Multi Drug Resistant Tuberculosis. J Young Pharm. Epub ahead of print 30 December 2013. [PubMed]
Brust J, Gandhi N, Wasserman S, et al. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study. Clin Infect Dis; 73. Epub ahead of print 21 April 2021. [PubMed]
Katrak S, Lowenthal P, Shen R, et al. Bedaquiline for Multidrug-Resistant Tuberculosis and QTc Prolongation in California. J Clin Tuberc Other Mycobact Dis 2021; 23: 100216. [PubMed]
Li M, Ramos LG. Drug-Induced QT Prolongation and Torsades de Pointes. P T 2017; 42: 473–477. [PubMed]
Rautaharju PM, Mason JW, Akiyama T. New Age- and Sex-Specific Criteria for QT Prolongation based on Rate Correction Formulas that Minimize Bias at the Upper Normal Limits. Int J Cardiol 2014; 174: 535–540. [PubMed]
Cunha JP. Sirturo. RxList, https://www.rxlist.com/sirturo-drug.htm (2021). [WebPage]
Priest B, Bell I, Garcia M. Role of hERG Potassium Channel Assays in Drug Development. Channels (Austin) 2008; 2: 87–93. [PubMed]
Kannankeril PJ, Norris KJ, Carter S, et al. Factors Affecting the Degree of QT Prolongation with Drug Challenge in a Large Cohort of Normal Volunteers. Heart Rhythm 2011; 8: 1530–1534. [PubMed]
Udwadia ZF, Ganatra S, Mullerpattan JB. Compassionate Use of Bedaquiline in Highly Drug-Resistant Tuberculosis Patients in Mumbai, India. Eur Respir J 2017; 49: 1601699.[PubMed]
Guglielmetti L, Jaspard M, le Dí» D, et al. Long-Term Outcome and Safety of Prolonged Bedaquiline Treatment for Multidrug-Resistant Tuberculosis. Eur Respir J 2017; 49: 1601799. [PubMed]
Cohen K, Maartens G. A Safety Evaluation of Bedaquiline for the Treatment of Multi-Drug Resistant Tuberculosis. Expert Opin Drug Saf 2019; 18: 875–882. [PubMed]
Gao JT, Du J, Wu GH, et al. Bedaquiline-Containing Regimens in Patients with Pulmonary Multidrug-Resistant Tuberculosis in China: Focus on the Safety. Infect Dis Poverty; 10. Epub ahead of print 1 December 2021. [PubMed]
Copyright (c) 2022 Vandu Primadana, Indra Yovi, Dyah Siswanti Estiningsih
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (